David Lebowitz
Stock Analyst at Citigroup
(2.47)
# 2,154
Out of 4,829 analysts
110
Total ratings
47.44%
Success rate
-1.25%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Neutral | $14 → $10 | $8.55 | +16.96% | 8 | May 9, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $86 → $80 | $32.13 | +148.99% | 2 | May 7, 2025 | |
| PLRX Pliant Therapeutics | Maintains: Neutral | $4 → $1.5 | $1.47 | +2.04% | 6 | Mar 4, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $45 → $49 | $35.68 | +37.33% | 3 | Feb 21, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $67 → $64 | $33.53 | +90.87% | 12 | Feb 20, 2025 | |
| EXEL Exelixis | Maintains: Buy | $38 → $45 | $36.98 | +21.69% | 2 | Feb 12, 2025 | |
| PTCT PTC Therapeutics | Maintains: Sell | $32 → $45 | $46.01 | -2.20% | 4 | Feb 12, 2025 | |
| INCY Incyte | Maintains: Buy | $97 → $88 | $60.85 | +44.62% | 5 | Feb 11, 2025 | |
| VKTX Viking Therapeutics | Initiates: Neutral | $38 | $28.30 | +34.28% | 1 | Feb 7, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $65 → $68 | $45.57 | +49.22% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $20.18 | +246.88% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $5.13 | +192.40% | 3 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $207 | $154.43 | +34.04% | 12 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $65 → $76 | $100.27 | -24.20% | 5 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $37 | $24.17 | +53.08% | 9 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $300.76 | +27.01% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $61.37 | +56.43% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $1.19 | +908.40% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $270.19 | -39.30% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $14.39 | +171.02% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $10.99 | +91.08% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $6.15 | +6,485.37% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $0.73 | +1,807.88% | 2 | Oct 12, 2021 |
Intellia Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $8.55
Upside: +16.96%
Cytokinetics
May 7, 2025
Maintains: Buy
Price Target: $86 → $80
Current: $32.13
Upside: +148.99%
Pliant Therapeutics
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.47
Upside: +2.04%
BridgeBio Pharma
Feb 21, 2025
Maintains: Buy
Price Target: $45 → $49
Current: $35.68
Upside: +37.33%
Ionis Pharmaceuticals
Feb 20, 2025
Maintains: Buy
Price Target: $67 → $64
Current: $33.53
Upside: +90.87%
Exelixis
Feb 12, 2025
Maintains: Buy
Price Target: $38 → $45
Current: $36.98
Upside: +21.69%
PTC Therapeutics
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $46.01
Upside: -2.20%
Incyte
Feb 11, 2025
Maintains: Buy
Price Target: $97 → $88
Current: $60.85
Upside: +44.62%
Viking Therapeutics
Feb 7, 2025
Initiates: Neutral
Price Target: $38
Current: $28.30
Upside: +34.28%
Mirum Pharmaceuticals
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $45.57
Upside: +49.22%
Oct 7, 2024
Initiates: Buy
Price Target: $70
Current: $20.18
Upside: +246.88%
Sep 24, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $5.13
Upside: +192.40%
Sep 17, 2024
Maintains: Buy
Price Target: $178 → $207
Current: $154.43
Upside: +34.04%
May 3, 2024
Maintains: Sell
Price Target: $65 → $76
Current: $100.27
Upside: -24.20%
May 2, 2024
Maintains: Buy
Price Target: $39 → $37
Current: $24.17
Upside: +53.08%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $300.76
Upside: +27.01%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $61.37
Upside: +56.43%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $1.19
Upside: +908.40%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $270.19
Upside: -39.30%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $14.39
Upside: +171.02%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $10.99
Upside: +91.08%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $6.15
Upside: +6,485.37%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $0.73
Upside: +1,807.88%